[go: up one dir, main page]

NO20014560D0 - Quinasoliner og terapautisk anvendelse derav - Google Patents

Quinasoliner og terapautisk anvendelse derav

Info

Publication number
NO20014560D0
NO20014560D0 NO20014560A NO20014560A NO20014560D0 NO 20014560 D0 NO20014560 D0 NO 20014560D0 NO 20014560 A NO20014560 A NO 20014560A NO 20014560 A NO20014560 A NO 20014560A NO 20014560 D0 NO20014560 D0 NO 20014560D0
Authority
NO
Norway
Prior art keywords
quinasolines
therapeutic use
therapeutic
Prior art date
Application number
NO20014560A
Other languages
English (en)
Other versions
NO20014560L (no
Inventor
Fatih M Uckun
Xing-Ping Liu
Rama K Narla
Original Assignee
Parker Hughes Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Parker Hughes Inst filed Critical Parker Hughes Inst
Publication of NO20014560L publication Critical patent/NO20014560L/no
Publication of NO20014560D0 publication Critical patent/NO20014560D0/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/94—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
NO20014560A 1999-03-19 2001-09-19 Quinasoliner og terapautisk anvendelse derav NO20014560D0 (no)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US12514599P 1999-03-19 1999-03-19
US12533899P 1999-03-19 1999-03-19
US12517799P 1999-03-19 1999-03-19
US09/357,404 US6258820B1 (en) 1999-03-19 1999-07-20 Synthesis and anti-tumor activity of 6,7-dialkoxy-4-phenylamino-quinazolines
PCT/US2000/006902 WO2000056720A1 (en) 1999-03-19 2000-03-16 Quinazolines and therapeutic use thereof

Publications (2)

Publication Number Publication Date
NO20014560L NO20014560L (no) 2001-09-19
NO20014560D0 true NO20014560D0 (no) 2001-09-19

Family

ID=27494574

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20014560A NO20014560D0 (no) 1999-03-19 2001-09-19 Quinasoliner og terapautisk anvendelse derav

Country Status (10)

Country Link
US (5) US6258820B1 (no)
EP (1) EP1163228A1 (no)
JP (1) JP2002540103A (no)
KR (1) KR20020011973A (no)
AU (1) AU4171900A (no)
CA (1) CA2367861A1 (no)
IL (1) IL144954A0 (no)
MX (1) MXPA01009453A (no)
NO (1) NO20014560D0 (no)
WO (1) WO2000056720A1 (no)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUP0102793A3 (en) * 1998-05-28 2002-07-29 Parker Hughes Inst St Paul Quinazolines for treating brain tumor and medicaments containing them
US6080747A (en) * 1999-03-05 2000-06-27 Hughes Institute JAK-3 inhibitors for treating allergic disorders
US6258820B1 (en) * 1999-03-19 2001-07-10 Parker Hughes Institute Synthesis and anti-tumor activity of 6,7-dialkoxy-4-phenylamino-quinazolines
US6126917A (en) * 1999-06-01 2000-10-03 Hadasit Medical Research Services And Development Ltd. Epidermal growth factor receptor binding compounds for positron emission tomography
GB9922171D0 (en) * 1999-09-21 1999-11-17 Zeneca Ltd Chemical compounds
AU1487001A (en) * 1999-11-15 2001-05-30 Parker Hughes Institute 4-(4'-hydroxyphenyl)amino-6,7-dimethoxyquinazoline to prevent development of colorectal cancer
US6482828B1 (en) 1999-11-15 2002-11-19 Parker Hughes Institute 4-(4′-hydroxyphenyl) amino-6,7-dimethoxyquinazoline to prevent development of colorectal cancer
JP2004504276A (ja) * 2000-06-26 2004-02-12 ザ、リージェンツ、オブ、ザ、ユニバーシティ、オブ、ミシガン ヒトの皮膚の光老化を防止するためのｅｇｆ−ｒタンパク質チロシンキナーゼ抑制剤の使用
TWI324597B (en) * 2002-03-28 2010-05-11 Astrazeneca Ab Quinazoline derivatives
US6924285B2 (en) 2002-03-30 2005-08-02 Boehringer Ingelheim Pharma Gmbh & Co. Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them
EP1521747B1 (en) * 2002-07-15 2018-09-05 Symphony Evolution, Inc. Receptor-type kinase modulators and methods of use
US7560558B2 (en) 2002-08-23 2009-07-14 Kirin Beer Kabushiki Kaisha Compound having TGFβ inhibitory activity and medicinal composition containing the same
US20060058325A1 (en) * 2002-12-24 2006-03-16 Astrazeneca Ab Therapeutic quniazoline derivatives
GB0317665D0 (en) 2003-07-29 2003-09-03 Astrazeneca Ab Qinazoline derivatives
MXPA06002964A (es) 2003-09-16 2006-06-14 Astrazeneca Ab Derivados de quinazolina como inhibidores de cinasa de tirosina.
GB0322409D0 (en) 2003-09-25 2003-10-29 Astrazeneca Ab Quinazoline derivatives
ES2925655T3 (es) * 2003-09-26 2022-10-19 Exelixis Inc Moduladores c-Met y métodos de uso
US7626030B2 (en) 2004-01-23 2009-12-01 Amgen Inc. Compounds and methods of use
KR20070026390A (ko) 2004-01-23 2007-03-08 암젠 인코포레이션 화합물 및 사용방법
EP1713781B1 (en) 2004-02-03 2008-11-05 AstraZeneca AB Quinazoline derivatives
BRPI0400869B8 (pt) * 2004-03-02 2021-05-25 Univ Estadual Campinas Unicamp novos compostos derivados de 4-anilinoquinazolinas com propriedade inibidora de adenosinacinases
KR100942865B1 (ko) * 2004-02-19 2010-02-17 렉산 파마슈티컬스, 인코포레이티드 퀴나졸린 유도체 및 이의 치료적 용도
JP2008521900A (ja) 2004-11-30 2008-06-26 アムジエン・インコーポレーテツド キノリン及びキナゾリン類似体並びにがん治療のための医薬としてのその使用
EP1871345B1 (en) * 2005-04-12 2012-08-01 Elan Pharma International Limited Nanoparticulate erlotinib formulations
JO2787B1 (en) 2005-04-27 2014-03-15 امجين إنك, Alternative amide derivatives and methods of use
EP1921070A1 (de) 2006-11-10 2008-05-14 Boehringer Ingelheim Pharma GmbH & Co. KG Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstelllung
EP2118075A1 (de) 2007-02-06 2009-11-18 Boehringer Ingelheim International GmbH Bicyclische heterocyclen, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung
CN101362719B (zh) * 2007-08-06 2012-04-18 北京师范大学 喹啉类衍生物以及包含其的组合物
CA2703257C (en) * 2007-10-29 2013-02-19 Amgen Inc. Benzomorpholine derivatives and methods of use
KR20100130583A (ko) 2007-11-28 2010-12-13 다나-파버 캔서 인스티튜트 인크. Ｂｃｒ-ａｂｌ의 소 분자 미리스테이트 억제제 및 이의 사용 방법
CN101939316B (zh) 2008-02-07 2013-10-02 贝林格尔.英格海姆国际有限公司 螺环杂环化合物、含有所述化合物的药物、其用途及其制备方法
BRPI0912170A2 (pt) 2008-05-13 2015-10-13 Astrazeneca Ab composto, forma a, processo para a preparação da mesma, composição farmacêutica, uso de um composto, e, método para tratar um câncer em um animal de sangue quente
US8648191B2 (en) 2008-08-08 2014-02-11 Boehringer Ingelheim International Gmbh Cyclohexyloxy substituted heterocycles, pharmaceutical compositions containing these compounds and processes for preparing them
CN101659658B (zh) * 2008-08-29 2014-04-02 北大方正集团有限公司 氰基取代的喹啉衍生物
KR20250123237A (ko) 2009-01-16 2025-08-14 엑셀리시스, 인코포레이티드 암의 치료를 위한 ｎ-（４-｛〔６，７-비스（메틸옥시）퀴놀린-4-일〕옥시｝페닐）-ｎ＇-（４-플루오로페닐）사이클로프로판-1,1-디카르복사미드의 말산염 및 그 결정형
UA108618C2 (uk) 2009-08-07 2015-05-25 Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку
WO2013143057A1 (zh) 2012-03-26 2013-10-03 中国科学院福建物质结构研究所 喹唑啉衍生物及用途
WO2017103931A1 (en) * 2015-12-17 2017-06-22 Biokine Therapeutics Ltd. Small molecules against cancer
AU2016371466B2 (en) 2015-12-17 2020-04-09 Alonbio Ltd Small Molecules for Inhibiting Chemokine Activity and/or Cancer Cells Growth
US20210113540A1 (en) * 2018-06-06 2021-04-22 National University Corporation Hokkaido University Treatment agent and pharmaceutical composition for glioma
WO2019235571A1 (ja) * 2018-06-06 2019-12-12 富士フイルム株式会社 血液がんの処置剤および医薬組成物
WO2019235572A1 (ja) * 2018-06-06 2019-12-12 富士フイルム株式会社 固形がんの処置剤および医薬組成物
AU2019309942B2 (en) * 2018-07-23 2025-08-14 Ohio State Innovation Foundation Derivatives of papaverine that are effective hypoxic tumor radiosensitizers
CA3090315C (en) 2019-05-15 2023-09-19 Biokine Therapeutics Ltd. 8-phenoxy-quinolinone derivatives for treating cancer, inhibiting chemokine activity and/or inducing cell death
WO2022086622A1 (en) * 2020-10-21 2022-04-28 Ohio State Innovation Foundation Methods to sensitize tumors to treatment by immunotherapy

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5538325A (en) 1978-09-11 1980-03-17 Sankyo Co Ltd 4-anilinoquinazoline derivative and its preparation
US4343940A (en) 1979-02-13 1982-08-10 Mead Johnson & Company Anti-tumor quinazoline compounds
US4559157A (en) 1983-04-21 1985-12-17 Creative Products Resource Associates, Ltd. Cosmetic applicator useful for skin moisturizing
LU84979A1 (fr) 1983-08-30 1985-04-24 Oreal Composition cosmetique ou pharmaceutique sous forme aqueuse ou anhydre dont la phase grasse contient un polyether oligomere et polyethers oligomeres nouveaux
US4820508A (en) 1987-06-23 1989-04-11 Neutrogena Corporation Skin protective composition
US4992478A (en) 1988-04-04 1991-02-12 Warner-Lambert Company Antiinflammatory skin moisturizing composition and method of preparing same
US4938949A (en) 1988-09-12 1990-07-03 University Of New York Treatment of damaged bone marrow and dosage units therefor
US5721237A (en) * 1991-05-10 1998-02-24 Rhone-Poulenc Rorer Pharmaceuticals Inc. Protein tyrosine kinase aryl and heteroaryl quinazoline compounds having selective inhibition of HER-2 autophosphorylation properties
US5480883A (en) * 1991-05-10 1996-01-02 Rhone-Poulenc Rorer Pharmaceuticals Inc. Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
US5710158A (en) * 1991-05-10 1998-01-20 Rhone-Poulenc Rorer Pharmaceuticals Inc. Aryl and heteroaryl quinazoline compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
AU661533B2 (en) * 1992-01-20 1995-07-27 Astrazeneca Ab Quinazoline derivatives
US6177401B1 (en) 1992-11-13 2001-01-23 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften Use of organic compounds for the inhibition of Flk-1 mediated vasculogenesis and angiogenesis
US5792771A (en) 1992-11-13 1998-08-11 Sugen, Inc. Quinazoline compounds and compositions thereof for the treatment of disease
US5712395A (en) * 1992-11-13 1998-01-27 Yissum Research Development Corp. Compounds for the treatment of disorders related to vasculogenesis and/or angiogenesis
WO1995024190A2 (en) * 1994-03-07 1995-09-14 Sugen, Inc. Receptor tyrosine kinase inhibitors for inhibiting cell proliferative disorders and compositions thereof
GB9510757D0 (en) 1994-09-19 1995-07-19 Wellcome Found Therapeuticaly active compounds
TW321649B (no) * 1994-11-12 1997-12-01 Zeneca Ltd
US5747498A (en) * 1996-05-28 1998-05-05 Pfizer Inc. Alkynyl and azido-substituted 4-anilinoquinazolines
CA2222545A1 (en) 1995-06-07 1996-12-19 Sugen, Inc. Quinazolines and pharmaceutical compositions
AU719434B2 (en) * 1996-02-13 2000-05-11 Astrazeneca Ab Quinazoline derivatives as VEGF inhibitors
ES2169355T3 (es) 1996-03-05 2002-07-01 Astrazeneca Ab Derivados de 4-anilinoquinazolina.
AU4342997A (en) 1996-09-13 1998-04-02 Sugen, Inc. Use of quinazoline derivatives for the manufacture of a medicament in the reatment of hyperproliferative skin disorders
US6004967A (en) * 1996-09-13 1999-12-21 Sugen, Inc. Psoriasis treatment with quinazoline compounds
HUP0102793A3 (en) 1998-05-28 2002-07-29 Parker Hughes Inst St Paul Quinazolines for treating brain tumor and medicaments containing them
US6258820B1 (en) * 1999-03-19 2001-07-10 Parker Hughes Institute Synthesis and anti-tumor activity of 6,7-dialkoxy-4-phenylamino-quinazolines

Also Published As

Publication number Publication date
IL144954A0 (en) 2002-06-30
US6358962B2 (en) 2002-03-19
CA2367861A1 (en) 2000-09-28
NO20014560L (no) 2001-09-19
WO2000056720A1 (en) 2000-09-28
US6258820B1 (en) 2001-07-10
US20010016588A1 (en) 2001-08-23
KR20020011973A (ko) 2002-02-09
US20040039002A1 (en) 2004-02-26
US20020137757A1 (en) 2002-09-26
AU4171900A (en) 2000-10-09
MXPA01009453A (es) 2002-05-14
EP1163228A1 (en) 2001-12-19
US6638939B2 (en) 2003-10-28
US20050075353A1 (en) 2005-04-07
JP2002540103A (ja) 2002-11-26
US7038049B2 (en) 2006-05-02

Similar Documents

Publication Publication Date Title
NO20014560D0 (no) Quinasoliner og terapautisk anvendelse derav
IS6411A (is) Kaspasa tálmar og notkun þeirra
DK1233964T3 (da) Ny anvendelse og hidtil ukendte N-azabicycloamidderivater
NO20021449D0 (no) Substituerte 2-tio-3,5-dicyano-4-aryl-6-aminopyridiner og anvendelse derav
DK1637127T3 (da) Terapeutisk mikroskum
DK1354888T3 (da) Glukopyranosyloxypyrazolderivater og anvendelse deraf i medikamenter
NO20012567D0 (no) Azepinoindolderivater, fremstilling og anvendelse derav
NO20021379D0 (no) Benzodiazepin-derivater, fremstilling og anvendelse derav
NO20022692L (no) Terapeutiske midler
DK1161434T3 (da) Pyridopyranoazepinderivater, deres fremstilling og terapeutiske anvendelse
DK1106607T3 (da) Uracilforbindelser og anvendelse deraf
DK1417189T3 (da) Acylaminothiazolderivater, fremstilling og terapeutisk anvendelse heraf
NO20012738D0 (no) Terapeutiske produkter og anvendelse derav
PT1178981E (pt) 3-piridil-4-arilpirrois substituidos e metodos terapeuticos e profilacticos
DK1140952T3 (da) Phosphororganiske forbindelser og anvendelse heraf
NO20030547D0 (no) Azabicykliske derivater og deres terapeutiske anvendelse
NO20016301D0 (no) Terapeutiske midler
AT4056U3 (de) Therapie- und trainingsgerät
NO20032821D0 (no) Sea-trosy og beslektede fremgangsmåter
EP1229795A4 (en) CHIMIOKINE BETA 13 HUMAN
NO20022482D0 (no) 2-arylkinolinderivater, fremgangsmåte og terapeutisk anvendelse derav
NO20021498D0 (no) PRV-1-genet og anvendelsen av dette
NO20023003L (no) Benzofenon-glykopyranosider, samt fremstilling og terapeutisk anvendelse
NO20015922D0 (no) Nye calpainer og anvendelse derav
NO991854A (no) Oppdrettsmær og anvendelse derav

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application